InspireMD, Inc. has announced its financial results for the third quarter of 2026, revealing a total revenue of $2.24 million. This update is significant as it reflects the company's ongoing efforts to strengthen its position in the surgical and medical instruments sector.

As of September 30, 2026, the company reported cash and cash equivalents totaling $19.25 million. These figures indicate a solid financial foundation as InspireMD navigates the competitive landscape of the surgical and medical instruments industry.

Background

InspireMD, Inc. is categorized under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company trades under the ticker symbol NSPR on the Nasdaq exchange. InspireMD has been actively involved in developing innovative medical technologies aimed at improving patient outcomes.

What the Filing Says

The recent SEC filing, dated November 12, 2026, highlights key financial results for the three and nine months ended September 30, 2026. The filing states, "For the third quarter of 2026, total revenue was $2,242,000." Additionally, it notes that cash and cash equivalents and marketable securities totaled $19,246,000 as of the same date.

Impact

This financial update may affect various stakeholders, including investors, employees, and competitors within the surgical and medical instruments sector. The reported revenue and cash reserves provide insights into InspireMD's operational effectiveness and market position.

What's Next

The filing does not specify what happens next for InspireMD, but the company is likely to continue focusing on its growth strategies and product development in the medical technology space.